Drug intelligence / Profile preview

LN-145 + durvalumab

Development stage: Unknown
Lead developer: Iovance Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
Administration: Intravenous

Overview

**LN-145 + durvalumab** is an experimental combination of two immunotherapies for advanced cancers, especially non-small cell lung cancer (NSCLC). LN-145 is an autologous tumor-infiltrating lymphocyte (TIL) therapy manufactured from a patient's tumor tissue, expanded ex vivo, and infused back following a preparative lymphodepletion regimen. Durvalumab is a human IgG1κ monoclonal antibody targeting programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to prevent tumor-mediated immune suppression. The combination aims to enhance antitumor immune responses: LN-145 provides immune effector cells, while durvalumab relieves immune checkpoint inhibition.

Other names: autologous TIL therapy + durvalumab

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on LN-145 + durvalumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LN-145 + durvalumab.

Explore the full profile